Rx DRUG PRICES AT PRODUCER LEVEL RISE 3.5% IN FIRST HALF
Rx DRUG PRICES AT PRODUCER LEVEL RISE 3.5% IN FIRST HALF of 1988 and are up 7.3% over the 12 months from June 1987 through June 1988, according to the Bureau of Labor Statistics' producer price index data. Manufacturers' drug prices increased only .5% during the second quarter, representing a mediating trend from the 8-10% annual price inflation in recent years. The second quarter is historically a slow period for price changes. Hormones (up 10.6%), minor tranquilizers (up 9.2%) and sedatives (also up 9.2%) led other drug categories with the biggest price run-ups during the April-to-June three-month period, according to the Bureau of Labor Statistics data. Rx drug categories on track to finish 1988 with price increases of 10% or more include CNS stimulants (up 10.6% since the beginning of the year), anticonvulsants (up 9.3%), and minor tranquilizers. Rx drug prices for the second quarter were outpaced by medical bulk chemicals, which rose 2.5% for the three months. For the half, bulk medical chemicals increased 2.3% in price at the manufacturer level. In recent years, bulk prices have lagged finished product price inflation. Since June 1982, bulk prices have actually declined over 3%. Prices for biological products at the producer level gain only .4% during the second quarter, and 1.1% for the half. OTC drug prices were flat during the second quarter and have grown 3.6% since the beginning of the year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth